Entire Transcript in Adobe Acrobat Format - National Reference ...

259
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
some tomorrow. People who cannot be here tomorrow, whether
they are on the subcommittee or on the full commission,
please give us any suggestions you have. We focused really
on one part of the report. We paid most of the attention
to that. A very important one and very critical to what we
are doing but there is a lot more there and we hope that
you will give us suggestions so that we can move forward
with the draft.
Jonathan?
DR. MORENO: Can I just say two things?
I have lots of things I would like to say but I
have exercised remarkable restraint, I think, over the last
hour.
It does seem to me that with respect to
research advance directives or whatever you want to call
them that this analogy with regard to end of life in a
clinical setting is important. Nobody has mentioned one
that the investigator has an incentive to sign up subjects
and use whatever device is available, which is not the
case, although I have tried to convince my physician
colleagues it is in their best interest to get their
patients signing advance directives in New York I have not
succeeded but I think investigators have an inherent
incentive to use devices such as this.